{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-107614","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2024-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.530311+00:00","generated_at":"2026-05-31T04:00:01.607054+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tivic Health receives IRB approval from Feinstein Institutes for ncVNS optimization study","bullets":["Received IRB approval from Feinstein Institutes for clinical optimization study of ncVNS; enrollment to commence.","Study will optimize stimulation parameters and electrode positioning using physiological measurements.","Data will guide selection of clinical populations and design of future disease-specific trials.","Collaboration with Fletcher Spaght to identify high-unmet-need clinical applications for ncVNS.","Global VNS market valued at $8.59B (2021), projected $21.3B by 2030, CAGR 10.6%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-107614","json":"https://secwatch.observer/filing/0000950170-24-107614.json","markdown":"https://secwatch.observer/filing/0000950170-24-107614.md","text":"https://secwatch.observer/filing/0000950170-24-107614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024107614/0000950170-24-107614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024107614/tivc-20240918.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:00:01.607054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}